SYNTHESIS AND CHARACTERIZATION OF ESTER PRODRUG OF MECLOFENAMIC ACID FOR REDUCTION OF ULCEROGENECITY

  • Niraj Kumar Oriental college of pharmacy, Bhopal (M.P.) India.
  • Julekha Siddiqui Oriental college of pharmacy, Bhopal (M.P.) India.
  • Kavita R. Loksh Oriental college of pharmacy, Bhopal (M.P.) India.

Abstract

The research studies also reported that the of the ester prodrugs are for enhancing the anti-inflammatory activity and for reduction of ulcerogenic effects of NSAIDs. Also the studies attempted to evaluate the pharmacokinetics of the prodrugs by in-vitro methods. The inflammation induced by carrageenan that is an acute model. The carriers used in research work, sesamol, umbelliferone and thymol, also produced anti-inflammatory activity and antioxidant effects .Therefore, overall, synthesized products showed synergistic anti-inflammatory activity. The natural phenolic antioxidants for synthesizing the ester prodrugs are sesamol, 4- methyl umbelliferone and thymol and that itself showed various pharmacological activities.

Keywords: NSAIDs, ester, antioxidants, thymol, inflammation, anti-inflammatory activity

References

1. Williams DA and Lemke TL, Foye’s Principles of Medicinal Chemistry, Lippincott Williams & Wilkins, 2002, 152.
2. Bodor N. and Buchwald P, Soft drug design: General principles and recent applications, Med. Res. Rev, 2000, 20: 58-101.
3. Harper NJ, Drug Res Prodrug: A Novel Approach of Drug Delivery Int. J. Pharm. Sci. Rev. Res., 25(1), Mar – Apr 2014, Article No. 32, 188-191.
4. Harle UN and Gaikwad NJ, Principle and Industrial application of Pharmacokinetics and Biopharmaceutics, Nirali Prakashan, Pune, 2008, 15.1-15.18.
5. Gray J.E., Weaver R. N., Moran J., and Feenstra E. S., The parenteral toxicity of clindamycin 2-phosphate in laboratory animals Toxicology and Applied Pharmacology 27, no. 2 (1974), 308-321.
6. Chakravarthi KG, Vijayaraj S, Venugopal A, Naresh Ch, Saritha B, Role of Prodrugs in Solubility Enhancement of Drugs, PharmaTutor, 2014, 2(12), 33-48.
7. Higuchi T, Stella V, ACS Symposium Series, Washington DC, American Chemical Society, 1975, 1-115.
8. Ragic Z, Kos G, Zorc B, Singh P, Singh S, Review on Concepts and Advances In Prodrug Technology, Acta Pharm. 2009, 59, 107-115.
9. Amidon G.L., Design of prodrugs based on enzymes-substrate specificity. In. Bundgaard, H., Design of Prodrugs. Elsevier, New York, 1985, 93-133.
10. Bhosale D, Bharambe S, Gairula N, Dhaneshwar SS, Mutual Prodrug Concept: Fundamentals and undamentals and Applications, Ind. J. Pharm. Sci. 2006, 68 (3), 286-294.
11. Jones, RONALD N., Barry A. L., and C. Thornsberry, Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetyl cefotaxime, Antimicrobial agents and chemotherapy 33, no. 6 (1989), 944-950.
12. Gennaro R, Alfanso W, Remington: The science and practice of pharmacy, Lippincott Williams & Wilkins, 2003, 20, 1, 913-914.
13. Nandy, Chandra B, Mazumder B, Pathak K, Saxena N, Jain S, Sharma S, Amishaben R, Shrivastava A, and Saxena P, An overview on fast dissolving drug delivery system, Asian Journal of pharmaceutical sciences and research 1, no. 2 (2011) 1-30.
14. Han HK, Amidon GL, Targeted prodrug design to optimize drug delivery, AAPS PharmSci. 2000, 2(1), E6. doi: 10.1208/ps020106.
15. Sznitowska M, Pryczkowska KZ, Jarvinen T, Review on Concepts and Advances In Prodrug Technology, Int. J. Pharm. 1999, 184(1), 115- 120.
16. Makhija T, Soman S, Scientometric Study of Doctoral Dissertations in Biochemistry in the University of Kerala, India Scholar research library, Der Pharmsia Lettre. 2010, 2(2), 300- 309.
17. Ueki R, Tanimoto M, Tatara T, Tsujimoto S, Anesthesia J, Application of Benford’s law a valuable tool for detecting scientific papers with fabricated data, 2007, 21 (3), 325-329.
18. KG Chakravarthi, S Vijayaraj, A Venugopal, Ch Naresh, B Saritha, Role of Prodrugs in Solubility Enhancement of Drugs, PharmaTutor, 2014, 2(12), 33-48.
Statistics
19 Views | 18 Downloads
How to Cite
Niraj Kumar, Julekha Siddiqui, and Kavita R. Loksh. “SYNTHESIS AND CHARACTERIZATION OF ESTER PRODRUG OF MECLOFENAMIC ACID FOR REDUCTION OF ULCEROGENECITY”. Current Research in Pharmaceutical Sciences, Vol. 14, no. 4, Jan. 2025, pp. 68-72, doi:10.24092/CRPS.2024.140402.
Section
Research Articles